Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03912194 · ClinicalTrials.gov registry record · Phase 3

Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation

A Phase 3 study of Tobacco Dependence, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
Phase 3
Development phase
400
Enrollment target
1
Study location

NCT03912194: Recruiting Phase 3 study of Tobacco Dependence, sponsored by University of Alabama at Birmingham.

NCT03912194 is a Phase 3 study of Tobacco Dependence that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 400 participants, below the 464-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03912194, a Phase 3 study of Tobacco Dependence, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
Phase 3
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

Smoking remains the single most preventable cause of morbidity and mortality in the United States, accounting for approximately half a million deaths every year. The current study will investigate the efficacy and mechanisms of change of a novel smoking cessation intervention. The current study will thus provide essential information regarding a treatment that has the potential to enhance the efficacy of existing smoking cessation interventions, thereby having a beneficial impact on the public health of the United States.

Primary Outcome

Self reported abstinence from smoking ("no smoking, not even a puff) in the past seven days, biochemically confirmed by a breath carbon monoxide reading of 3 or less

Conditions Studied

Interventions

  • BEHAVIORAL cognitive-behavioral withdrawal regulation strategies
  • BEHAVIORAL relaxation strategies
  • BEHAVIORAL early withdrawal exposure

Study Locations (1)

Alabama

  • Ryals Public Health Building - Birmingham

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2019-08-01
Est. Completion 2026-07-01
Phase Phase 3
University of Alabama at Birmingham

1,160 total trials

What NCT03912194 shows while recruiting

NCT03912194 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 464-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (14% lower).

The record links to 1 condition, with Tobacco Dependence appearing as the primary indexed condition, and to 3 interventions - of which cognitive-behavioral withdrawal regulation strategies is the first listed.

NCT03912194 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT03912194 about?

NCT03912194 is a clinical study titled "Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation". Smoking remains the single most preventable cause of morbidity and mortality in the United States, accounting for approximately half a million deaths every year. The current study will investigate the efficacy and mechanisms of change of a novel smoking cessation intervention. The current study will...

What is the current status of trial NCT03912194?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2019-08-01. Estimated completion is 2026-07-01.

What conditions does trial NCT03912194 study?

This clinical trial studies the following conditions: Tobacco Dependence.

What interventions are being tested in trial NCT03912194?

The interventions under investigation include: cognitive-behavioral withdrawal regulation strategies (BEHAVIORAL), relaxation strategies (BEHAVIORAL), early withdrawal exposure (BEHAVIORAL).

Who is sponsoring clinical trial NCT03912194?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03912194 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03912194's enrollment target sits among peer trials

400 10th of 28 higher than 19 of 28 other Tobacco Dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03912194, the US trial registry maintained by the National Library of Medicine. NCT03912194 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.